Download the whitepaper to learn more.
Genomics-only testing approaches leave a gap in patient care, as only a fraction of the patients are eligible for targeted therapy.
This whitepaper explores how integrating epigenomic biomarkers can help enhance patient identification and better stratify patients for treatment responsiveness by revealing new insights into tumor behavior, evolution, and resistance patterns that genomic profiling alone may miss.
Epigenomic biomarkers can improve biopharma’s drug development programs by:
- Improving clinical outcomes
- Supporting label expansion
- Building physician confidence to drive adoption
- Enabling personalized medicine positioning to enhance scientific credibility and payer traction
By adopting this integrated approach, biopharma teams can strengthen evidence generation, accelerate successful drug development, and advance more personalized cancer care.
Offered Free by: Guardant Health
See All Resources from: Guardant Health
